Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has priced a registered direct offering of 3.5 million equity units at $2 apiece, giving the transaction a $7 million value.

Each unit consists of one share of Cancer Genetics' common stock and one warrant to buy an additional share at an exercise price of $2.35. The warrants are exercisable six months after the date of issuance, and expire 18 months after issuance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.